The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: Braveheart Buys Stake In RMS From Brown

Wed, 01st Jul 2020 17:15

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and Wednesday and not separately reported by Alliance News:

----------

Remote Monitored Systems PLC - London-based majority owner of GyroMetric Systems Ltd, which provides digital monitoring and safeguarding systems for rotating shafts on wind turbines - Braveheart Investment Group PLC buys 119.6 million shares from Executive Director Trevor Brown at 0.275 pence, worth GBP329,003, on Tuesday. Brown is chief executive officer of Braveheart, and payment for the RMS shares is in new Braveheart shares issued to Brown. Following the transaction, Braveheart owns 18.1% of RMS, and Brown has no interest. Brown now has a 24.8% stake in Braveheart. RMS owns 58% of GyroMetric and Braveheart owns 19.5%. Brown will remain on the RMS board to represent Braveheart.

----------

Savills PLC - London-based estate agent - James Sparrow, CEO of Savills UK & EMEA, sells 4,096 shares at GBP8.33, worth GBP34,100, on Friday last week. Still holds 58,475 shares.

----------

Babcock International Group PLC - London-based engineering services for defence - Chair Ruth Cairnie and associate buy 10,000 shares in total at GBP3.12 and GBP3.15, worth GBP31,333, on Wednesday.

----------

Qinetiq Group PLC - Farnborough, Hampshire-based security and defence contractor - Non-Executive Director Susan Searle buys 10,000 shares at GBP3.0244, worth GBP30,244, on Wednesday.

----------

Walker Greenbank PLC - Denham, Buckinghamshire-based interior furnishings - Non-Executive Director Christopher Rogers buys 52,500 shares at 37p, worth GBP19,425, on Tuesday. Now has 75,000 shares.

----------

Renew Holdings PLC - Leeds-based engineering services for infrastructure - Non-Executive Director Shatish Dasani and wife Dina buy 10,000 shares total at 444p, worth GBP44,400, on Tuesday. Dasani now interested in 15,000 shares.

----------

Staffline Group PLC - Nottingham-based recruitment and training firm - Three directors buy GBP70,857 in shares on Tuesday. Executive Chair Ian Lawson buys 131,577 shares at 39.00p, worth GBP51,315. Interim Chief Financial Officer Daniel Quint buys 25,320 shares at average 39.49p, worth GBP9,209. Non-Executive Director Richard Thomson buys 25,857 shares at average 39.96p, worth GBP10,333.

----------

Solid State PLC - Redditch, Worcestershire-based electronic components - Finance Director Peter James buys 2,520 shares at GBP5.95, worth GBP14,994. Now has 3,204 shares. Matthew Richards, managing director of subsidiary Steatite Ltd, buys 2,900 shares at GBP5.91, worth GBP17,126. Now has 10,375 shares. Both on Tuesday.

----------

ECSC Group PLC - Bradford-based cybersecurity firm - CEO Ian Mann buys 29,827 shares at average 67p, worth GBP19,984, on Wednesday. Now has 2.3 million shares, a 23% stake.

----------

Redx Pharma PLC - Macclesfield-based cancer and fibrosis drugs - Non-Executive Chair Iain Ross buys 215,870 shares at average 18.94p, worth GBP40,886, on Tuesday. Non-Executive Director Peter Presland buys 118,849 shares at 25p, worth GBP29,712, also on Tuesday. Both purchases are their only holdings.

----------

Trackwise Designs PLC - Tewkesbury, Gloucestershire-based printed circuit technology - Non-Executive Director Charles Cattaneo buys 10,000 shares at 86p, worth GBP8,600, on Tuesday. The shares are his only holding.

----------

UIL Ltd - closed-end Bermuda-incorporated investment company - Non-Executive Director Stuart Bridges buys 6,080 shares at 180p, worth GBP10,944, on Wednesday.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
10 Jul 2019 10:40

WINNERS & LOSERS SUMMARY: PageGroup Slumps After Profit Warning

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - LOSERS----------Micro Focus down

Read more
10 Jul 2019 09:41

Redx Pharma Shares Double After Jazz Pharmaceutical Deal

(Alliance News) - Redx Pharma PLC said Wednesday it has signed a definitive agreement with Nasdaq-listed Jazz Pharmaceuticals PLC to sell its pan-RAF inhibitor programme.Shares in the and a

Read more
10 Jun 2019 10:10

Redx Pharma Gets GBP2.5 Million Financing As Interim Loss Narrows

LONDON (Alliance News) - Redx Pharma PLC on Monday said its loss narrowed in the first half of its current financial year as it progresses on cancer and idiopathic pulmonary fibrosis drugs the and

Read more
10 Jun 2019 08:29

Redx Pharma narrows losses as RXC004 trials recommence

(Sharecast News) - Drug discovery and development company Redx Pharma published its interim results on Monday, revealing it had narrowed first-half losses as it progresses on cancer and idiopathic pulmonary fibrosis drugs development.

Read more
3 May 2019 14:07

Redx Pharma Exploring New Financing Options Despite Progress

LONDON (Alliance News) - Cancer and fibrosis-focused drug firm Redx Pharma PLC is "greatly encouraged" by talks over securing new financing.In November, Redx said it was looking a

Read more
3 May 2019 11:17

Redx Pharma extends cash runway into July

(Sharecast News) - Drug discovery and development company Redx Pharma updated the market on its ongoing plans to strengthen its balance sheet on Friday, with its board reiterating its commitment to strengthening the balance sheet in order to extend the cash runway beyond the second quarter of 2019, as it initially announced in November.

Read more
12 Feb 2019 13:42

Redx Pharma reveals promising data on 'ROCK2' compound

(Sharecast News) - Drug discovery and development company Redx Pharma announced promising preclinical efficacy data for its lead selective 'ROCK2' compound on Tuesday.

Read more
12 Feb 2019 09:45

Redx Pharma Sees Promising Results From Liver Disease Treatment

LONDON (Alliance News) - Redx Pharma PLC said Tuesday that preclinical efficacy data for its ROCK2 compound showed the product was able to have an impact on established fibrosis.Shares in a

Read more
6 Feb 2019 11:45

Redx Pharma Receives Oustanding Loan Amounts From Redag

LONDON (Alliance News) - Redx Pharma PLC on Wednesday said that it received a full cash repayment of GBP869,126, representing the outstanding amount of a loan made in 2014 to Redag Crop Protection

Read more
31 Jan 2019 11:03

Deinove Backs Out Of Anti-Infective NBTI Programme With Redx Pharma

LONDON (Alliance News) - Redx Pharma PLC on Thursday said French biotech firm Deinove SA will not exercise its option for Redx's novel bacterial topoisomerase inhibitor programme.Shares

Read more
31 Jan 2019 09:45

Deinove hands rights to NBTI programme back to Redx Pharma

(Sharecast News) - Drug discovery and development company Redx Pharma announced on Thursday that Deinove had decided not to exercise its option for Redx's 'Novel Bacterial Topoisomerase Inhibitor' (NBTI) programme.

Read more
30 Nov 2018 10:36

Redx Pharma Drug Candidate RXC006 To Be Developed As Fibrosis Drug

LONDON (Alliance News) - Drug developer Redx Pharma PLC said Friday its RXC006 drug candidate was able to suppress lung fibrosis in living organisms and will be developed as a treatment for in up

Read more
30 Nov 2018 10:31

Redx Pharma jumps as first data shows 'great potential' for fibrosis candidate

(Sharecast News) - Redx Pharma made gains on Friday after it said that pre-clinical data suggested that its RXC006 drug candidate has "great potential" as a treatment for fibrosis.

Read more
19 Nov 2018 13:07

Redx Pharma Posts Large Annual Loss, Appoints Astra Executive As CFO

LONDON (Alliance News) - Redx Pharma PLC on Monday posted a large loss due to the absence of a big exceptional disposal gain seen a year before and said that it has appointed James Mead as its new

Read more
19 Nov 2018 08:59

Redx Pharma swings to a loss following 'seminal' year

(Sharecast News) - A year after clambering out of administration, drug discovery and development outfit Redx Pharma swung to a loss but remains confident of making progress with a drug pipeline refocused on cancer and fibrosis.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.